World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT01983657
Date of registration: 07/11/2013
Prospective Registration: No
Primary sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Public title: Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. PAP
Scientific title: Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.
Date of first enrolment: January 2012
Target sample size: 40
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT01983657
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
China
Contacts
Name:     Huiping Li, Doctor
Address: 
Telephone: 86-13817389991
Email: liw2013@126.com
Affiliation: 
Name:     Huiping Li, Dr
Address: 
Telephone:
Email:
Affiliation:  Shanghai Pulmonary Hospital, Shanghai, China
Name:     Huiping Li, Dr
Address: 
Telephone: 86-13817389991
Email: liw2013@126.com
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosed PAP patients

- Aged 17-80

- Signed informed consent

Exclusion Criteria:

- Secondary PAP

- Received whole lung lavage therapy within 4 weeks before enrollment

- Received previous GM-CSF therapy within 6 months before enrollment

- WBC=12,000/ul

- fever=38?

- Severe edema, severe liver, kidney, lung and cardiovascular disease.

- Pregnant,planning to get pregnant or nursing

- Inability to express the subjective discomfort

- Serious drug allergy history, E.coli preparation or rhGM-CSF serious allergy history



Age minimum: 17 Years
Age maximum: 80 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Pulmonary Alveolar Proteinosis
Intervention(s)
Procedure: Whole Lung Lavage(WLL)
Drug: rhGM-CSF
Primary Outcome(s)
Improvements in double pulmonary diffuse lesions (Chest CT score ) [Time Frame: 6 months]
Secondary Outcome(s)
Clinical symptoms observation: shod of breath, cough (according to each score standard) [Time Frame: 6 months]
Improvements in pulmonary function [Time Frame: 6 months]
Improvements in arterial blood gas, including alveolar-arterial oxygen difference(A-aDO2), partial pressure of oxygen(PaO2), partial pressure of carbon dioxide in artery(PaCO2), arterial oxygen saturation(SaO2). [Time Frame: 6 months]
Granulocyte Macrophage Colony Stimulating Factor(GM-CSF) Antibody titer change [Time Frame: 6 months]
Secondary ID(s)
20120401
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history